Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 22, 2011. The registrant is a Delaware corporation headquartered in Annapolis, Maryland. The report discloses specific corporate governance changes and litigation updates occurring on or around the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial operational and legal events rather than financial performance data.
Material Changes
- Executive Departure: Charles A. Reinhart III resigned as Chief Financial Officer. The resignation is effective September 7, 2011.
- Litigation Status: The Company has not received a decision from the Court of Chancery of Delaware regarding pending litigation with Siga Technologies Inc., nor has it received specific information regarding the timing of such a decision.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future performance. The primary risk disclosed is the uncertainty surrounding the outcome and timing of the pending litigation with Siga Technologies Inc.
Investor Verification Checklist
- Verify the appointment of a new Chief Financial Officer to replace Charles A. Reinhart III.
- Monitor the Court of Chancery of Delaware for updates on the PharmAthene vs. Siga Technologies Inc. litigation.
- Confirm the effective date of the CFO resignation (September 7, 2011) against internal corporate records.